Elon Musk said on Oct. 30, 2026, that Neuralink’s Blindsight was ready from an engineering standpoint and awaiting regulatory approval. The FDA Breakthrough Device Designation Neuralink announced for Blindsight is a separate status, not authorization to market the implant.
What the FDA designation means
Neuralink announced on Sept. 17, 2024, that Blindsight had received FDA Breakthrough Device Designation. The FDA’s program is intended to speed the development and review of certain devices. Designation does not itself authorize marketing; devices still have to meet applicable safety and effectiveness requirements to receive authorization. (FDA guidance; Neuralink’s announcement)
How Neuralink describes Blindsight
Neuralink describes Blindsight as a proposed visual prosthesis: a video camera captures a person’s surroundings and sends information wirelessly to an implant intended to activate brain areas responsible for visual function. That is the company’s description of the design, not a reported clinical outcome. (Neuralink’s visual-prosthesis page)
Neuralink describes future trials in the United States and directs interested people to its patient registry for updates when those trials launch. Joining the registry is a way to receive information, not trial enrollment.
